Influenza A virus DNA vaccine H1N1 - Vical

Drug Profile

Influenza A virus DNA vaccine H1N1 - Vical

Alternative Names: Influenza A (H1N1) DNA vaccine - Vical; Pandemic influenza plasmid DNA vaccine H1N1- Vical; Swine flu DNA vaccine - Vical; Vaxfectin®-formulated plasmid DNA vaccine H1N1 - Vical

Latest Information Update: 07 Mar 2014

Price : $50

At a glance

  • Originator Vical
  • Class Influenza A virus H1N1 vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Suspended Influenza A virus H1N1 subtype

Most Recent Events

  • 07 Mar 2014 Influenza A virus DNA vaccine H1N1 - Vical is available for licensing as of 31 Dec 2011. http://www.vical.com
  • 31 Dec 2011 Suspended - Phase-I for Influenza-A virus H1N1 subtype in USA (IM)
  • 27 Apr 2011 Immunogenicity and adverse events data from a phase I trial in Influenza-A virus H1N1 subtype infections released by Vical
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top